| EPSRC Reference: |
EP/S010289/1 |
| Title: |
Bioorthogonal Gold Chemistry to Explore Novel Biomedical Applications |
| Principal Investigator: |
Unciti-Broceta, Professor A |
| Other Investigators: |
|
| Researcher Co-Investigators: |
|
| Project Partners: |
|
| Department: |
Edinburgh Cancer Research Centre |
| Organisation: |
University of Edinburgh |
| Scheme: |
Standard Research |
| Starts: |
01 October 2018 |
Ends: |
31 March 2022 |
Value (£): |
513,211
|
| EPSRC Research Topic Classifications: |
| Catalysis & Applied Catalysis |
Chemical Biology |
| Med.Instrument.Device& Equip. |
|
|
| EPSRC Industrial Sector Classifications: |
| No relevance to Underpinning Sectors |
|
|
| Related Grants: |
|
| Panel History: |
| Panel Date | Panel Name | Outcome |
|
01 Aug 2018
|
HT Investigator-led Panel Meeting - Aug 2018
|
Announced
|
|
|
Summary on Grant Application Form |
Drugs used in the treatment of pain, for instance sciatica or hernia back pain, can cause serious unwanted side-effects to such a level that patients are forced to choose between symptoms (dizziness, sickness, constipation, depression) and the pain. These side effects are common in the nervous system (e.g. the brain) because they are also treatments for other conditions like anxiety and epilepsy. This unmet clinical need calls for the development of smarter medications that only work where needed, that target site of pain with no effect on the rest of the body.
To provide a safer and more effective strategy to treat localised pain, we have devised a new approach that chemically-deactivates the drugs, so they no longer have an effect. They can be reactivated with the use of gold, which would be encapsulated in a small device and implanted at the site of pain or the spine. Orally-given inactive drug precursors will only become "active" at the pain site upon interaction with the gold device, with minimal side effects. This technology is based on a novel strategy pioneered at the Edinburgh Cancer Research Centre at the University of Edinburgh that enables full control over where the therapy takes action.
In order to develop this concept, we need to first find the most effective way to deactivate the drugs, and prevent them from causing any effect, then test how quickly and efficiently they are reactivated by the gold in a biological setting. We also need to research the best way to protect the gold from attack by the body to prevent the dulling of its ability to activate the drugs over time.
Between one-third and one-half of the UK suffer from chronic pain, but this figure is expected to increase with an ageing population. Nerve pain due to sciatica and other issues including diabetes, infection and cancer, affects over 8% of the UK population. Patients suffering from multiple sclerosis, cerebral palsy, spinal cord injury and complex regional pain syndrome, for example, would be the beneficiaries of this treatment, and there is potential to expand the technology to many other chronic diseases such as Parkinson's. Due to its novelty, it will make a major impact in the pharmaceutical sector and, in turn, to the NHS and people of the UK and worldwide by improving the quality-of-life of people suffering from pain.
|
|
Key Findings |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Potential use in non-academic contexts |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Impacts |
|
| Description |
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk |
| Summary |
|
| Date Materialised |
|
|
|
|
Sectors submitted by the Researcher |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
| Project URL: |
|
| Further Information: |
|
| Organisation Website: |
http://www.ed.ac.uk |